Zacks Research Brokers Lower Earnings Estimates for Neogen

Key Points

• Zacks Research cut its Q4 2026 EPS estimate for Neogen from $0.07 to $0.03, while the consensus full-year EPS remains about $0.22.
• Neogen recently reported earnings of $0.09 (beating the $0.04 consensus) on $211.2M revenue, but revenue was down 4.4% year-over-year and the company showed a deeply negative net margin (~69.9%).
• Analyst sentiment is mixed with an average rating of Hold and a $10.67 price target; the stock trades near $9.53 with a market cap of roughly $2.07B and a negative P/E.

Neogen Corporation (NASDAQ:NEOG - Free Report) - Equities research analysts at Zacks Research lowered their Q4 2026 earnings estimates for shares of Neogen in a research report issued to clients and investors on Thursday, April 30th. Zacks Research analyst Team now forecasts that the company will earn $0.03 per share for the quarter, down from their previous forecast of $0.07. The consensus estimate for Neogen's current full-year earnings is $0.22 per share.

Neogen (NASDAQ:NEOG - Get Free Report) last released its quarterly earnings results on Thursday, April 9th. The company reported $0.09 earnings per share for the quarter, topping the consensus estimate of $0.04 by $0.05. Neogen had a negative net margin of 69.93% and a positive return on equity of 2.35%. The firm had revenue of $211.20 million during the quarter, compared to the consensus estimate of $204.62 million. The business's revenue for the quarter was down 4.4% on a year-over-year basis.

Several other research analysts also recently weighed in on NEOG. Wall Street Zen downgraded shares of Neogen from a "buy" rating to a "hold" rating in a research report on Saturday, April 11th. Weiss Ratings restated a "sell (d-)" rating on shares of Neogen in a research report on Friday, April 10th. Piper Sandler restated a "neutral" rating and set a $10.00 price target (up from $6.50) on shares of Neogen in a research report on Monday, January 12th. Guggenheim restated a "buy" rating and set a $12.00 price target (up from $8.00) on shares of Neogen in a research report on Friday, January 9th. Finally, William Blair restated a "market perform" rating on shares of Neogen in a research report on Monday, March 2nd. Two research analysts have rated the stock with a Buy rating, three have issued a Hold rating and one has issued a Sell rating to the company. According to MarketBeat, Neogen presently has an average rating of "Hold" and an average price target of $10.67.

Neogen Price Performance

NEOG opened at $9.53 on Monday. Neogen has a twelve month low of $4.53 and a twelve month high of $11.43. The company has a quick ratio of 2.84, a current ratio of 3.92 and a debt-to-equity ratio of 0.38. The company has a 50-day moving average price of $9.70 and a 200 day moving average price of $8.40. The company has a market cap of $2.07 billion, a PE ratio of -3.40, a price-to-earnings-growth ratio of 4.33 and a beta of 1.84.

Institutional Trading of Neogen

A number of hedge funds have recently bought and sold shares of NEOG. UMB Bank n.a. raised its holdings in Neogen by 238.2% in the 4th quarter. UMB Bank n.a. now owns 6,422 shares of the company's stock valued at $45,000 after acquiring an additional 4,523 shares during the last quarter. Hantz Financial Services Inc. raised its holdings in Neogen by 816.9% in the 4th quarter. Hantz Financial Services Inc. now owns 7,592 shares of the company's stock valued at $53,000 after acquiring an additional 6,764 shares during the last quarter. Cresset Asset Management LLC purchased a new stake in shares of Neogen in the 2nd quarter valued at approximately $53,000. Evergreen Capital Management LLC purchased a new stake in shares of Neogen in the 2nd quarter valued at approximately $56,000. Finally, Northwestern Mutual Wealth Management Co. grew its stake in shares of Neogen by 3,158.4% in the 4th quarter. Northwestern Mutual Wealth Management Co. now owns 8,309 shares of the company's stock valued at $58,000 after buying an additional 8,054 shares during the period. Institutional investors and hedge funds own 96.73% of the company's stock.

About Neogen

Neogen Corporation is a global provider of food and animal safety products, offering a broad portfolio of diagnostic and testing solutions. Headquartered in Lansing, Michigan, the company develops and manufactures tests designed to detect foodborne pathogens, allergens and toxins in food, beverage and environmental samples. Since its founding in 1982, Neogen has focused on delivering rapid, accurate and user‐friendly assays to food processors, grain handlers and quality laboratories around the world.

In the food safety arena, Neogen's product lineup includes immunoassay kits, molecular diagnostics and enrichment media for pathogens such as Salmonella, Listeria and E.

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest reporting and unbiased coverage. Please send any questions or comments about this story to contact@marketbeat.com.